ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lisinopril

Also written as “LP-003 Injection”, “lisinopril” and “LP-005 Injection”.

Its studies are mostly in Hypertension · Chronic Urticaria · Hemoglobinuria, Paroxysmal · Fasting · Rhinitis, Allergic, Seasonal, led by 10 companies.

Drug pageLisinopril: every studyMany companies study it; this page follows only the 39 they lead. All 79 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 5, 202539 company-led studies, 12 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Longbio Pharma149 open or runningphase 3since Dec 5, 2025Jun 27, 2023Nov 2026phase 1 · NCT06604949
GlaxoSmithKlineits history only60 open or runningphase 3since Apr 13, 2005Apr 13, 2005none ahead
Novartisits history only60 open or runningphase 4since Sep 12, 2005Sep 10, 2005none ahead
IPCA Laboratoriesits history only40 open or runningphase 1since Nov 5, 2012Nov 5, 2012none ahead
Longbio Pharma (Suzhou)its history only33 open or runningphase 2since Apr 23, 2026Apr 23, 2026Jul 16, 2027phase 2 · NCT07816432
Par Healthits history only20 open or runningphase 1since Apr 1, 2008Apr 1, 2008none ahead
Ascension Healthits history only10 open or runningphase 4since Jan 2, 2018Jan 2, 2018none ahead
Dexa Medica Groupits history only10 open or runningno phasesince Sep 1, 2013Sep 1, 2013none ahead
Intarcia Therapeuticsits history only10 open or runningphase 1since Dec 21, 2015Dec 21, 2015none ahead
Pharmtechnologyits history only10 open or runningphase 1since Sep 20, 2021Sep 20, 2021none ahead

Also a collaborator on its studies: PharmaKinetics Laboratories.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Longbio Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 27, 2023First study: phase 2 study in Rhinitis, Allergic, SeasonalFirst studyNCT06046391 · 180 enrolled · China
  2. Jan 18, 2024Phase 2 study in Chronic UrticariaNCT06228560 · 202 enrolled · China
  3. Feb 3, 20243 phase 1 studiesNCT06294301, NCT06294288, NCT06294275
  4. Sep 14, 2024Phase 1 study in Chronic UrticariaNCT06604949 · 12 enrolled · China
  5. Aug 15, 2025Phase 2 study in Allergic DiseasesNCT07148557 · 6 enrolled · China
  6. Sep 30, 2025Phase 2 study in Hemoglobinuria, ParoxysmalNCT07212426 · 30 enrolled · China
  7. Nov 24, 2025Phase 2 study in Hemoglobinuria, ParoxysmalNCT07266155 · 30 planned · China
  8. Dec 5, 2025Phase 3 study in Rhinitis, Allergic, SeasonalPhase 3 reachedNCT07291284 · 546 enrolled · China
  9. Dec 11, 20252 phase 2 studiesNCT07342803, NCT07313917
  10. Jan 15, 2026Phase 2 study in Complement-mediated Renal DiseasesNCT07363265 · 46 planned · China
  11. Nov 9, 2026Phase 3 study in Chronic UrticariaNCT07946913 · 514 planned · China

Ahead

  1. Nov 2026Primary completion: phase 1 study in Chronic UrticariaNCT06604949
  2. Feb 28, 2027Primary completion: phase 2 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07313917
  3. Dec 28, 2027Primary completion: phase 2 study in Allergic AsthmaNCT07342803
  4. Dec 30, 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT07266155

TargetBeta

ACE →read by rule
“An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity”NCIt, by rule
“Angiotensin-converting enzyme inhibitor”ChEMBL 37, by rule

Studies

All 14 Longbio Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07946913Chronic Urticaria · China3Not yet recruitingMar 24, 2028514
NCT07363265Complement-mediated Renal Diseases · China2Not yet recruitingAug 2, 202846
NCT07313917Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · China2Not yet recruitingFeb 28, 2027150
NCT07342803Allergic Asthma · China2RecruitingDec 28, 2027200
NCT07291284Rhinitis, Allergic, Seasonal · China3Active, not recruitingMar 31, 2026546
NCT07266155Hemoglobinuria, Paroxysmal · China2Not yet recruitingDec 30, 202730
NCT07212426Hemoglobinuria, Paroxysmal · China2Active, not recruitingMay 6, 202630
NCT07148557Allergic Diseases · China2Active, not recruitingMay 31, 20266
NCT06604949Chronic Urticaria · China1Active, not recruitingNov 202612
NCT06294288Chronic Urticaria · China1CompletedMar 4, 202460
NCT06294275Myelodysplastic Syndromes · China1CompletedAug 16, 202368
NCT06294301Hemoglobinuria, Paroxysmal · China1CompletedAug 31, 202468
NCT06228560Chronic Urticaria · China2CompletedApr 17, 2025202
NCT06046391Rhinitis, Allergic, Seasonal · China2CompletedOct 19, 2023180

How it is read

Names in the registry

  • “Lisinopril”, 10 entries
  • “LP-003 Injection”, 5 entries
  • “lisinopril”, 5 entries
  • “LP-005 Injection”, 4 entries
  • “LP-003”, 2 entries

Codes read as this program: LP003, LP005, LP001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.